ROCKVILLE, Md., Sept. 6,
2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:
RGNX) today announced it will participate in the following upcoming
Morgan Stanley 20th Annual Global Healthcare
September 14, 2022
Fireside chat: 2:55 p.m.
Location: Sheraton Hotel, New
UBS Biotech South Beach Conference 2022
September 29, 2022
Location: Mondrian South Beach, Miami, FL
A live webcast of the Morgan Stanley 20th Annual Global
Healthcare Conference fireside chat can be accessed in the
Investors section of REGENXBIO's website at www.regenxbio.com. An
archived replay of the webcast will be available for approximately
30 days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates,
including late-stage and commercial programs, in multiple
therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to
progress five AAV Therapeutics from our internal pipeline and
licensed programs into pivotal-stage or commercial products by
Chris Brinzey, ICR Westwicke
View original content to download
SOURCE REGENXBIO Inc.